Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
01
06
2023
accepted:
20
09
2023
pmc-release:
31
10
2024
medline:
3
11
2023
pubmed:
2
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
Neurodegeneration is considered a relevant pathophysiologic feature in neurologic disorders associated with antibodies against glutamic acid decarboxylase 65 (GAD65). In this study, we investigate surrogates of neuroaxonal damage in relation to disease duration and clinical presentation. In a multicentric cohort of 50 patients, we measured serum neurofilament light chain (sNfL) in relation to disease duration and disease phenotypes, applied automated MRI volumetry, and analyzed clinical characteristics. In patients with neurologic disorders associated with GAD65 antibodies, we detected elevated sNfL levels early in the disease course. By contrast, this elevation of sNfL levels was less pronounced in patients with long-standing disease. Increased sNfL levels were observed in patients presenting with cerebellar ataxia and limbic encephalitis, but not in those with stiff person syndrome. Using MRI volumetry, we identified atrophy predominantly of the cerebellar cortex, cerebellar superior posterior lobe, and cerebral cortex with similar atrophy patterns throughout all clinical phenotypes. Together, our data provide evidence for early neuroaxonal damage and support the need for timely therapeutic interventions in GAD65 antibody-associated neurologic disorders.
Identifiants
pubmed: 37914416
pii: 11/1/e200176
doi: 10.1212/NXI.0000000000200176
pmc: PMC10624332
pii:
doi:
Substances chimiques
Autoantibodies
0
glutamate decarboxylase 2
EC 4.1.1.15
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Neurol Neuroimmunol Neuroinflamm. 2021 Oct 1;8(6):
pubmed: 34599001
Mov Disord. 2021 Oct;36(10):2273-2281
pubmed: 33951232
JAMA Neurol. 2014 Aug;71(8):1009-16
pubmed: 24934144
Neurol Neuroimmunol Neuroinflamm. 2023 May 25;10(4):
pubmed: 37230543
J Neurol Neurosurg Psychiatry. 2021 Feb 9;:
pubmed: 33563803
Neurol Neuroimmunol Neuroinflamm. 2023 Feb 23;10(3):
pubmed: 36823135
Nat Rev Neurol. 2016 Oct;12(10):563-74
pubmed: 27632903
Neuroimage. 2004 Oct;23(2):724-38
pubmed: 15488422
Neurology. 2023 May 23;100(21):e2204-e2213
pubmed: 37015822
N Engl J Med. 2001 Dec 27;345(26):1870-6
pubmed: 11756577
Neuroimage. 2022 Dec 1;264:119703
pubmed: 36349595
Neuroimage Clin. 2021;32:102826
pubmed: 34563986
Neurology. 2019 Mar 5;92(10):e1007-e1015
pubmed: 30737333
Brain. 2023 Apr 19;146(4):1436-1452
pubmed: 36314080
Neurology. 2021 May 18;96(20):e2546-e2557
pubmed: 33795390